bosentan anhydrous has been researched along with Alloxan Diabetes in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 16 (59.26) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arias, L; Bogdanov, P; Durán, V; Garcia-Ramírez, M; Guerrero, M; Hernández, C; Montoro, B; Ramos, H; Sampedro, J; Simó, R; Simó-Servat, O; Solà-Adell, C; Suñé-Negre, JM; Ticó, JR | 1 |
| Abdelsaid, M; Coucha, M; Ergul, A; Ma, H | 1 |
| Abdelsaid, M; Coucha, M; Ergul, A; Kaczmarek, J | 1 |
| Jaggi, AS; Sharma, B; Singh, G; Singh, N | 1 |
| Ayaz, G; Baygutalp, NK; Bayir, Y; Calik, M; Demirci, E; Ferah, I; Gundogdu, C; Ozkanlar, S | 1 |
| Akpinar, E; Atmaca, HT; Bayraktutan, Z; Cadirci, E; Cayir, Y; Demir, I; Demir, R; Kunak, CS; Un, H; Yayla, M | 1 |
| Akpinar, E; Albayrak, A; Atmaca, HT; Bayraktutan, Z; Cayir, A; Cayir, Y; Kara, M; Kose, D; Ugan, RA | 1 |
| Alkan, E; Balbay, MD; Basar, MM; Halici, Z; Karakus, E; Ugan, RA; Un, H | 1 |
| Feng, QZ; Li, M; Shi, ZG; Yang, B | 1 |
| Arikawa, E; Dumont, AS; Lee, S; McNeill, JH; Verma, S; Yao, L | 1 |
| Clozel, M; Ding, SS; Hess, P; Qiu, C; Xi, JF; Zheng, N | 1 |
| Bellini, G; Bernobich, E; Borri, A; Cosenzi, A; Milutinovic, N; Trevisan, R | 1 |
| Chakrabarti, S; Cukiernik, M; Gonder, JR; Khan, ZA | 1 |
| Ammar, el SM; Said, SA; Suddek, GM | 1 |
| Jiang, J; Macleod, KM; McNeill, JH; Zhang, L | 1 |
| Jiang, J; McNeill, JH; Xiang, H; Yuen, V | 1 |
| Berkowitz, BA; Luan, H; Roberts, R | 1 |
| Ding, Y; Judd, RL; Zhong, J; Zou, R | 1 |
| Stevens, EJ; Tomlinson, DR | 1 |
| Chakrabarti, S; Deng, D; Downey, D; Evans, T; Mukherjee, K | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Rumble, JR; van Eeden, P | 1 |
| Chakrabarti, S; Chen, S; Deng, DX; Evans, T | 1 |
| Cai, L; Chakrabarti, S; Chen, S; Deng, DX; Evans, T; Mukherjee, K | 1 |
| Arikawa, E; Dumont, AS; McNeill, JH; Verma, S | 1 |
| Arikawa, E; McNeill, JH; Verma, S | 1 |
| Chakrabarti, S; Chen, S; Cukiernik, M; Deng, D; Evans, T | 1 |
| Allen, TJ; Burrell, LM; Cao, Z; Casley, D; Cooper, ME; Davis, BJ; Johnston, CI; Lassila, M; Tikkanen, I; Tikkanen, T | 1 |
27 other study(ies) available for bosentan anhydrous and Alloxan Diabetes
| Article | Year |
|---|---|
Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes.
Topics: Administration, Topical; Animals; Apoptosis; Bosentan; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin-1; Female; Glial Fibrillary Acidic Protein; Humans; Immunohistochemistry; In Situ Nick-End Labeling; In Vitro Techniques; Male; Rabbits | 2018 |
Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.
Topics: Animals; Bosentan; Cerebrovascular Circulation; Diabetes Mellitus, Experimental; Endothelin B Receptor Antagonists; In Vitro Techniques; Metabolome; Metformin; Middle Cerebral Artery; Muscle Development; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasoconstriction; Vasodilation | 2014 |
Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
Topics: Animals; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Hyperglycemia; Middle Cerebral Artery; Neovascularization, Pathologic; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vascular Remodeling | 2014 |
Efficacy of bosentan, a dual ETA and ETB endothelin receptor antagonist, in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Bosentan; Brain; Dementia; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelium, Vascular; Glutathione; Male; Nitrates; Nitrites; Rats; Rats, Wistar; Streptozocin; Sulfonamides | 2014 |
Endothelin receptor inhibition with bosentan delays onset of liver injury in streptozotocin-induced diabetic condition.
Topics: Animals; Bosentan; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Glutathione; Liver; Male; Malondialdehyde; Rats; Streptozocin; Sulfonamides; Superoxide Dismutase; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Does bosentan protect diabetic brain alterations in rats? The role of endothelin-1 in the diabetic brain.
Topics: Animals; Antioxidants; Bosentan; Brain; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Male; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Streptozocin; Sulfonamides | 2015 |
The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.
Topics: Acute Lung Injury; Animals; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Glutathione; Lung; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Sulfonamides; Superoxide Dismutase; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Role of endothelin receptors and relationship with nitric oxide synthase in impaired erectile response in diabetic rats.
Topics: Animals; Apomorphine; Bosentan; Diabetes Mellitus, Experimental; Dopamine Agonists; Endothelin Receptor Antagonists; Endothelin-1; Erectile Dysfunction; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Penile Erection; Penis; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tumor Necrosis Factor-alpha | 2017 |
Bosentan ameliorates the expression of fibrotic related growth factors and collagen-1 in diabetic mice.
Topics: Animals; Bosentan; Collagen; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; RNA, Messenger; Streptozocin; Sulfonamides; Vascular Endothelial Growth Factor A | 2012 |
Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan.
Topics: Animals; Bosentan; Coronary Circulation; Coronary Vessels; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Endothelin-1; In Vitro Techniques; Male; Rats; Rats, Wistar; Sulfonamides; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2002 |
Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Endothelin A Receptor Antagonists; Glomerular Filtration Rate; Kidney; Male; Organ Size; Rats; Rats, Wistar; Sulfonamides; Vasoconstriction | 2003 |
Nephroprotective effect of bosentan in diabetic rats.
Topics: Animals; Blood Glucose; Bosentan; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Fibronectins; Kidney; Rats; Rats, Inbred WKY; Sulfonamides; Transforming Growth Factor beta | 2003 |
Oncofetal fibronectin in diabetic retinopathy.
Topics: Aged; Animals; Blotting, Western; Bosentan; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin-1; Endothelium, Vascular; Female; Fibronectins; Gene Silencing; Humans; Male; Middle Aged; Rats; Rats, Sprague-Dawley; Retinal Perforations; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation; Vitrectomy; Vitreous Body | 2004 |
Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes.
Topics: Animals; Blood Glucose; Bosentan; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Insulin; Male; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stress, Physiological; Sulfonamides | 2005 |
Effect of chronic endothelin blockade on PKC isoform distribution in mesenteric arteries from diabetic rats.
Topics: Animals; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Enzyme Induction; Isoenzymes; Mesenteric Artery, Superior; Protein Kinase C; Protein Transport; Rats; Subcellular Fractions; Sulfonamides | 2005 |
Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms.
Topics: Animals; Blood Glucose; Bosentan; Cell Fractionation; Cell Membrane; Cytosol; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Enzyme Activation; Glucose; Insulin; Isoenzymes; Male; Myocardium; Protein Kinase C; Rats; Rats, Wistar; Receptors, Endothelin; Sulfonamides; Ventricular Function, Left | 2006 |
Blocking ET-1 receptors does not correct subnormal retinal oxygenation response in experimental diabetic retinopathy.
Topics: Animals; Apyrase; Bosentan; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Magnetic Resonance Imaging; Oxygen; Oxygen Consumption; Partial Pressure; Rats; Retina; Retinal Vessels; Sulfonamides | 2006 |
Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Body Weight; Bosentan; Calcium Channels, L-Type; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Male; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Rats; Receptor, Endothelin A; Sulfonamides | 2006 |
Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Bosentan; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Heart Rate; Injections, Intravenous; Laser-Doppler Flowmetry; Male; Neural Conduction; Rats; Rats, Wistar; Sciatic Nerve; Streptozocin; Sulfonamides | 1995 |
Diabetes-induced vascular dysfunction in the retina: role of endothelins.
Topics: Animals; Antihypertensive Agents; Autoradiography; Bosentan; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Immunohistochemistry; Male; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Retina; Retinal Vessels; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Ultrasonography, Doppler, Color | 1999 |
Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
Topics: Animals; Antihypertensive Agents; Blotting, Northern; Bosentan; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin Receptor Antagonists; Endothelium, Vascular; Epidermal Growth Factor; Extracellular Matrix; Gene Expression; Hypertrophy; In Situ Hybridization; Male; Mast Cells; Mesenteric Arteries; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides | 2000 |
Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats.
Topics: Animals; Basement Membrane; Bosentan; Capillaries; Collagen; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Extracellular Matrix; Fibronectins; Galactose; Gene Expression; Male; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Retina; Retinal Vessels; RNA, Messenger; Sulfonamides | 2000 |
Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism.
Topics: Animals; Apoptosis; Bosentan; Diabetes Mellitus, Experimental; Endothelin-1; Endothelins; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Testis | 2000 |
Chronic bosentan treatment improves renal artery vascular function in diabetes.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Bosentan; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Norepinephrine; Rats; Rats, Wistar; Renal Artery; Sulfonamides; Time Factors; Vasoconstriction; Vasoconstrictor Agents | 2001 |
Long-term endothelin receptor blockade improves cardiovascular function in diabetes.
Topics: Animals; Antihypertensive Agents; Atrial Function, Left; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Endothelin-1; Male; Mesenteric Arteries; Myocardial Contraction; Rats; Rats, Wistar; Sulfonamides; Vasoconstriction | 2001 |
Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins.
Topics: Animals; Antihypertensive Agents; Basement Membrane; Bosentan; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelins; Fibronectins; Galactose; Humans; Kidney; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides | 2002 |
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart; Kidney; Male; Metalloendopeptidases; Myocardium; Neprilysin; Organ Size; Organophosphonates; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Tetrazoles | 2002 |